Manufacturer consolidation
Winners will be biotechs and products that deliver: Systemic metabolic platforms Therapies combining fat loss with muscle preservation Long-term maintenance and relapse-prevention solutions Adherence, formulation, and delivery innovations Losers will be biotechs or products characterized by: Mono-organ, late-stage interventions Products without meaningful weight or metabolic impact Incremental add-ons justified by biomarker shifts alone Startups at Strategic Risk in the Post-GLP-1++ Era Retatrutide does not merely compete with other drugs it raises the minimum threshold of relevance
Notably, the deals struck include an expansion of coverage of GLP-1s to include some Medicare patients who previously had no access to GLP-1s for obesity alone
Over time, and with the accumulation of data from these individualized assessments, the dosage of Wegovy (semaglutide) may be increased
Off the bike, make sure that protein consumption stays high, as it will help your body hold on to lean muscle
But this knowledge will make every storage decision you make more informed and more effective
